Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients.
We evaluated different culture conditions to obtain a lineage-selected proliferation of clonogenic megakaryocytic progenitors (MP). In low-density (LD) or CD34+ cell cultures, the best results were obtained in serum-free medium in the presence of megakaryocyte growth and development factor, stem cell factor, interleukin-3 (IL-3), IL-6, IL-11, FLT-ligand, and macrophage inflammatory protein-1alpha. In paired studies, expansion of LD cells was less effective than expansion of CD34+ cells, and pre-enrichment of CD34+ cells using negative depletion of lineage-positive cells produced significantly larger quantities of MP than pre-enrichment using positive selection. MP proliferation peaked on day 7 in culture, and an 8- +/- 5-fold expansion of CD34+/CD61+ cells, a 17- +/- 5-fold expansion of colony-forming units-megakaryocytes, and a 58- +/- 14-fold expansion of the total number of CD61+ cells was obtained. In a feasibility clinical study, 10 cancer patients (8 with breast cancer and 2 with non-Hodgkin's lymphoma) undergoing autologous peripheral blood progenitor cell (PBPC) transplant received MP generated ex vivo (range, 1 to 21 x 10(5)/kg CD61 cells) together with unmanipulated PBPC. Eight patients received a single allogeneic platelet transfusion, whereas platelet transfusion support was not needed in 2 of the 4 patients receiving the highest doses of cultured MP. This result compares favorably with a retrospective control group of 14 patients, all requiring platelet transfusion support. Adverse reactions or bacterial contamination of cell cultures have not been observed. In conclusion, MP can be expanded ex vivo and safely administered to autologous transplant recipients. Further clinical trials will indicate the reinfusion schedule able to consistently abrogate the need for allogeneic platelet transfusion support in autologous transplantation.
Bertolini
F
F
Division of Medical Oncology, IRCCS Maugeri Foundation, Pavia Medical Center, Italy.
Battaglia
M
M
Pedrazzoli
P
P
Da Prada
G A
GA
Lanza
A
A
Soligo
D
D
Caneva
L
L
Sarina
B
B
Murphy
S
S
Thomas
T
T
della Cuna
G R
GR
D002478:Cells, Cultured; D016895:Culture Media, Serum-Free; D046508:Culture Techniques / Q000379:methods; D016207:Cytokines / Q000494:pharmacology; D005240:Feasibility Studies; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D008533:Megakaryocytes / Q000637:transplantation*; D009369:Neoplasms / Q000097:blood / Q000628:therapy; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000628:therapy; D014182:Transplantation, Autologous
D016895:Culture Media, Serum-Free; D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors